CTSD

Across TCGA pan-cancer cohorts, CTSD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTSD data layer compared with 22 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CTSD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTSD expression acts as an unfavorable survival marker.

CESC, LGG, and CHOL are the cancer types where CTSD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.116	0.587	.025	12	view →
LGG	OS	Median	All	0.208	0.896	<.001	12	view →
CHOL	DFS	Median	All	0.037	0.486	.001	6	view →
HNSC	OS	Median	All	0.175	0.603	.022	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTSD–CESC (OS)

Open the CESC breakdown →